A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

Also called NCT03350321

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 162 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03350321
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03350321. Randomized; no masking; primary purpose treatment. Start 2017-12-12 (actual); primary completion 2019-05-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects
Acronym
MIYABI ND-C
Condition
Anemia
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Molidustat (BAY85-3934)
Intervention (Drug)
Darbepoetin alfa
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct03350321
Content hash
b4793a8f732b3e93f4530b37e89581ea7856d1bf774f1a151d526db243c6e8e4